Modality
Radioligand
MOA
IL-17i
Target
AuroraA
Pathway
Neuroinflam
LGS
Development Pipeline
Preclinical
~Feb 2013
→ ~May 2014
Phase 1
~Aug 2014
→ ~Nov 2015
Phase 2
~Feb 2016
→ ~May 2017
Phase 3
~Aug 2017
→ ~Nov 2018
NDA/BLA
~Feb 2019
→ ~May 2020
Approved
Aug 2020
→ Oct 2030
ApprovedCurrent
NCT06822644
1,726 pts·LGS
2020-08→2030-10·Not yet recruiting
1,726 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2030-10-194.6y awayPh3 Readout· LGS
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Approved
Not yet…
Catalysts
Ph3 Readout
2030-10-19 · 4.6y away
LGS
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06822644 | Approved | LGS | Not yet recr... | 1726 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ARG-3458 | Argenx | Preclinical | RET | |
| ARG-6988 | Argenx | Preclinical | AuroraA | |
| Nidaratamab | Krystal Biotech | Preclinical | RET |